

Express Mail No.: EJ770265105US
Date of Deposit: February 1, 2002

Page 1 of 1

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/019,356
	Filing Date	10/22/01
	First Named Inventor	Slater
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24356-001 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
	A1						

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
KAC	B1	WO 98/42835	Otsuka Pharmaceutical Co. LTD	October 1, 1998		

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
KAC	C1	Hopfner et al. (1998). <i>Biochem and Biophys Res Comm</i> 251: 811-817.
	C2	Nawa et al. (1999). <i>British J. of Cancer</i> 80: 1185-1189.
	C3	Urano et al. (1997). <i>Cancer Research</i> 57: 3281-3287.
	C4	Wurl et al. (1998). <i>Oncogene</i> 16: 1183-1185.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	7/10/05
---------------------------	--	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1624516v1

TRA 1622056v1



Express Mail Label: EV 392157420 US
Date of Deposit: May 3, 2004

Page 1 of 1
Attorney Docket No.: 24356-001 NATL

Please type a plus sign (+) in this box

+

Modified Form 1449/PTO				Application Number		10/019,356	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date		May 21, 2002	
				First Named Inventor		Slater	
				Group Art Unit		1641	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		24356-001 NATL	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
KAC	B2	WO 95/33048	GLAXO GROUP LIMITED	12/07/95			
KAC	B3	WO 97/41222	SMITHKLINE BEECHAM P.L.C.; HUMAN GENOME SCIENCES INC.	11/06/97			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
KAC	C5	Di Virgilio, et al., <i>Drug Dev. Res.</i> , 45:207-213 (1998).					
	C6	Gröschel-Stewart, et al., <i>Cell Tissue Res.</i> , 296:599-605 (1999).					
	C7	Hansen, et al., <i>J. Neurol.</i> , 27:529-539 (1998).					
	C8	Vulchanova, et al., <i>Neuropharmacol.</i> , 36(9):1229-1242 (1997).					
	C9	Supplementary European Search Report, mailing date December 9, 2002.					

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>Harmon G. Gamella</i>	Date Considered	7/10/05
-----------------------	--------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.